The short version of peptide analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== For acute coronary syndrome === The combination of a P2Y12 inhibitor and aspirin, called dual antiplatelet treatment, remains the first-line treatment for acute coronary syndrome. A 2019 randomized trial suggested that prasugrel is superior to ticagrelor.
== Structure == Rat monitor peptide is composed of 61 amino acids (compared to 56 in humans) with a molecular weight of approximately 6500 daltons and is basic (PI = 9.0), acid stable, and heat resistant. It is only found in the zymogen granules of pancreatic acinar cells.
In September 1981, shortly after Mahathir assumed office as prime minister, the country carried out the "Dawn Raid", a calculated operation orchestrated by Permodalan Nasional Berhad (PNB) to regain majority ownership of Guthrie, one of the largest British-owned plantation companies at the time. This move symbolized a broader effort under Mahathir's leadership to reduce foreign dominance over Malaysia's economy and reclaim control of national assets. A month after the Dawn Raid, Mahathir introduced the "Buy British Last" (BBL) policy, which lasted from October 1981 to March 1983. The reason for this policy was rooted in several grievances with Britain. Britain's decision to abolish tuition fee subsidies for Commonwealth students placed a heavy financial burden on Malaysia, which had to cover the increased costs for approximately 17,000 Malaysian students studying in the UK. Additionally, British media criticism of Malaysia's internal policies further strained relations. The BBL policy, which directed government ministries and agencies to deprioritize British goods and services, significantly affected Britain, causing estimated losses of between £15.5 million and £50 million in the early months. This eventually led to negotiations, culminating in Mahathir and British Prime Minister Margaret Thatcher meeting in 1983 to resolve the tensions and end the policy. Mahathir later recalled persuading Thatcher that raising tuition fees was a mistake, leading Thatcher to introduce scholarships for Malaysian students.
Sources: en.wikipedia.org
== Aerobic vs anaerobic == Anaerobic organisms require an oxygen-free environment. When culturing anaerobic microbes, broths are often flushed with nitrogen gas to extinguish oxygen present, and growth can also occur on media in a chamber without oxygen present. Sodium resazurin can be added to indicate redox potential. Cultures are to be incubated in an oxygen-free environment for 48 hours at 35 °C before growth is examined.
=== Equilibrative nucleoside transporters (ENTs) === The nucleoside transporters, or equilibrative nucleoside transporters, are uniporters that transport nucleosides, nucleobases, and therapeutic drugs across the cell membrane. Nucleosides serve as building blocks for nucleic acid synthesis and are key components for energy metabolism in creating ATP/ GTP. They also act as ligands for purinergic receptors such as adenosine and inosine. ENTs allow the transport of nucleosides down their concentration gradient. They also have the ability to deliver nucleoside analogs to intracellular targets for the treatment of tumors and viral infections. ENTs are part of the Major Facilitator Superfamily (MFS) and are suggested to transport nucleosides using a clamp-and-switch model. In this model, the substrate first binds to the transporter, which leads to a conformational change that forms an occluded state (clamp). Then, the transporter switches to face the other side of the membrane and releases the bound substrate (switching). ENTs have been found in protozoa and mammals. In humans, they have been discovered as ENT3 (hENT1-3) and ENT4 (hENT4) transporters. ENTs are expressed across all tissue types, but certain ENT proteins have been found to be more abundant in specific tissues. hENT1 is found mostly in the adrenal glands, ovary, stomach and small intestines. hENT2 is expressed mostly in neurological tissues and small parts of the skin, placenta, urinary bladder, heart muscle and gallbladder.
== Diaphragm and peristaltic pumps == In order to avoid leakage at the packing or seal particularly when a liquid is dangerous, toxic, or noxious, diaphragm pumps are used for metering. Diaphragm pumps have a diaphragm through which repeated compression/decompression motion is transmitted. The liquid does not penetrate through the diaphragm, so the liquid inside the pump is sealed off from the outside. Such motion changes the volume of a chamber in the pump head so that liquid enters through an inlet check valve during decompression and exits through an outlet check valve during compression, in a manner similar to piston pumps. Diaphragm pumps can also be made which discharge at fairly high pressure. Diaphragm metering pumps are commonly hydraulically driven. Peristaltic pumps use motor-driven rollers to roll along flexible tubing, compressing it to push forward a liquid inside. Although peristaltic pumps can be used to meter at lower pressures, the flexible tubing is limited in the level of pressure it can withstand.
Many hormones and their structural and functional analogs are used as medication. The most commonly prescribed hormones are estrogens and progestogens (as methods of hormonal contraception and as HRT), thyroxine (as levothyroxine, for hypothyroidism) and steroids (for autoimmune diseases and several respiratory disorders). Insulin is used by many diabetics. Local preparations for use in otolaryngology often contain pharmacologic equivalents of adrenaline, while steroid and vitamin D creams are used extensively in dermatological practice. A "pharmacologic dose" or "supraphysiological dose" of a hormone is a medical usage referring to an amount of a hormone far greater than naturally occurs in a healthy body. The effects of pharmacologic doses of hormones may be different from responses to naturally occurring amounts and may be therapeutically useful, though not without potentially adverse side effects. An example is the ability of pharmacologic doses of glucocorticoids to suppress inflammation.
Sources: en.wikipedia.org
== Career == In 1898, she founded the Philadelphia Clinical Laboratory and conducted bacteriological analyses. She educated farmers on the handling of raw milk in order to improve the safety of ice cream sold at local schools. In the same year, she accepted a position with the Women's Medical College of Pennsylvania as director of their clinical laboratory. She also served as a research worker in the department of hygiene at the University of Pennsylvania from 1898 to 1901, and was a bacteriologist with the Philadelphia Bureau of Health. In her position with the Bureau of Health, she was instrumental in improving sanitation standards for the handling of milk and milk products.
In addition, they also used petroleum to cover their bodies against insect bites and as a form of jelly to prevent their skins from drying out. Peyote – indigenous people realized the antibiotic property of peyote and used the extract to treat fevers and enhance the energy in their bodies and treatment as an anesthetic. Pineapple – indigenous people residing in what is now Brazil and the Paraná River valley of Paraguay were the first to cultivate the pineapple. From there, pineapple cultivation spread to Mexico, Central and South America and the Caribbean. Indigenous Americans used the pineapple as a source of food. Planned city construction – ancient cities in Mexico–such as Teotihuacan and the Aztec capital of Tenochtitlan–incorporated planned city design, including streets laid out in a grid pattern. Plumbing – the Maya have been found to be the earliest inventors of plumbing in Mesoamerica, with the earliest example of a pressurized water system being constructed in 750 CE—or earlier. This pressurized water system was located in the Maya site of Palenque, where public baths and toilets were accessible to the residents of the ancient city. Poncho – worn by indigenous Americans in central Mexico, the Andes and Patagonia. Popcorn – Indigenous Americans were among the earliest peoples to develop popcorn, with evidence of popcorn dating back thousands of years in the Americas. Potato – The potato was domesticated 7,000–10,000 years ago in the highlands of southern Peru and northwestern Bolivia near Lake Titicaca.
=== Ornithine decarboxylase === Ornithine decarboxylase (ODC), is a labile protein that is the first rate-limiting enzyme in polyamine biosynthesis. Its degradation is regulated by antizyme that is induced by polyamine production. NQO1 has been shown to stabilize the degradation of ODC by binding to it and protecting it from 20S proteasomal degradation.
The most commonly performed 15N experiment is the 1H-15N HSQC. The experiment is highly sensitive and therefore can be performed relatively quickly. It is often used to check the suitability of a protein for structure determination using NMR, as well as for the optimization of the sample conditions. It is one of the standard suite of experiments used for the determination of the solution structure of protein. The HSQC can be further expanded into three- and four dimensional NMR experiments, such as 15N-TOCSY-HSQC and 15N-NOESY-HSQC.
PVDF is a thermoplastic that expresses versatility for applications similar to other thermoplastics, particularly fluoropolymers. PVDF resin is heated and handled for use in extrusion and injection molding to produce PVDF pipes, sheets, coatings, films, and molded PVDF products, such as bulk containers. Common industry applications for PVDF thermoplastics include:
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.